

December 15, 2025

News Release

Company: Olympus Corporation
Bob White, Director, Representative Executive Officer, President and CEO
(Code: 7733, Prime, Tokyo Stock Exchange)
Contact: Takaaki Sakurai, Vice President, Investor Relations
TEL: +81-42-642-2111

Notice Regarding Additional Investment in Corporate Venture Capital Fund “Olympus Innovation Ventures Fund II”

Olympus Corporation ("Olympus") hereby announces today that it has dedicated a second tranche of funding, to its corporate venture capital fund, Olympus Innovation Ventures, LLC (“OIV”).

1. Background and Purpose

Olympus announced, on November 7, 2025, our new corporate strategy ("Corporate Strategy") to build on our evolution as a global MedTech company, defining our next chapter. Under this Corporate Strategy, we aim to achieve innovation-driven growth with an annual revenue growth rate of 3-5% based on a next wave of innovation and expansion into faster-growing segments.

We strive to fortify Olympus’ portfolio through focused investments; shape the future of endoscopy through OLYSENSE and robotics; enhance performance in China and set direction for emerging markets; and drive M&A tuck-ins in close adjacencies

In order to take advantage of these opportunities and to create opportunities for us to grow, we have dedicated a new, larger amount of funding (USD 150 million) to Olympus Innovation Ventures Fund II (“OIV Fund II”), OIV Fund II will allow us to continue to build relationships with early-stage companies and help nurture partnerships with relevant and compelling entrepreneurial teams.

This additional funding will be deployed over the years depending on investment opportunities identified by OIV. The timing and amounts of individual investments by OIV have not yet been determined.

2. Overview of Olympus Innovation Ventures

(1) Company Name	Olympus Innovation Ventures, LLC
(2) Address	800 West Park Drive, Westborough, MA 01581, US
(3) Title and Name of Representative	President, Gabriela Kaynor
(4) Description of business	Investment in and support to external opportunities
(5) Investment amount	USD 200 million(approximately JPY 31.3 billion (Note1)) (Total Investment Amount for OIV Fund II : USD 150 million (approximately JPY 23.5 billion (Note1)) (Note2)
(6) Date of incorporation	Oct 5, 2021
(7) Investors and investment ratios	Olympus Corporation of the Americas – 100%
(8) Fiscal Year	The fiscal year ends on March 31.

(9) Relationship between Olympus and Olympus Innovation Ventures	Capital Relationship	OIV is established through a 100% investment by a consolidated subsidiary of Olympus.
	Personnel Relationship	Executive officers of Olympus and an employee of a consolidated subsidiary of Olympus concurrently serve as directors of OIV.
	Transactional Relationship	Nil

(Note1) Calculated at the exchange rate of JPY 156.63 per USD (exchange rate as of the end of November 2025).

(Note2) We plan to invest up to a total of USD 200 million over the years.

(Note3) Olympus Corporation of the Americas is a consolidated subsidiary of Olympus.

3. Future Outlook

Olympus initially committed USD 50 million for Olympus Innovation Ventures Fund I (“OIV Fund I”). Like OIV Fund I, OIV Fund II will identify, vet and invest in early-stage companies with differentiated technologies.

Olympus believes that OIV Fund II will not have a material impact on its financial results for the year ending March 31, 2026. If any future event which requires disclosure arises, we will announce it promptly.

For more information about Olympus Ventures please contact:

Olympus Innovation Ventures, LLC

Abigail Hunter-Syed

Global Head of Venture Investing

abigail.syed@olympus.com

800 West Park Drive, Westborough, MA 01581 United States